A ‘brain training’ iPad game developed and tested by researchers at the University of Cambridge may improve the memory of patients with schizophrenia, helping them in their daily lives at work and living independently, according to research published today.
A new responsive material ‘glued’ together with short strands of DNA, and capable of translating thermal and chemical signals into visible physical changes, could underpin a new class of biosensors or drug delivery systems.
Technology developed at the University of Cambridge lies at the heart of a commercial process that can turn toothpaste tubes and drinks pouches into both aluminium and fuel in just three minutes.
The University invested £2.7 million last year to support the development of Cambridge spin-outs.
Cambridge Innovation Capital announces first three investments from its £50 million Cambridge Cluster fund12 Aug 2014
Cambridge Innovation Capital (CIC), an investor in high-growth technology companies in the Cambridge cluster, has completed its first investments from a £50 million fund, backing three companies in the areas of cloud-based video archiving, grid-scale energy management and generative music composition.
Sir Keith O’Nions named Board Chairman of Cambridge Enterprise
A new transformative point-of-care diagnostic which gives instant results for the detection of genetic material from the HIV virus is being rolled out across Africa. The small, highly portable machine - known as SAMBA II - will help transform the lives of millions, especially HIV exposed infants who have a one in two chance of early death if HIV infection is not diagnosed within the first six weeks of life and if they are not immediately initiated on treatment.
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.
Children with type 1 diabetes have been able to use pioneering artificial pancreas technology, developed at the University of Cambridge, for the first time overnight at home without the supervision of researchers.